Atlas Trials

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL

Clinical trial NCT07244406 · RECRUITING

Trial details

NCT number
NCT07244406
Sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
B-ALL
Start date
2025-01-10
Primary completion
2027-03-31
Enrollment
59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.